INTRODUCTION
In 2007, a joint Expert Panel convened by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) met to develop guidelines for when and how to test for the human epidermal growth factor receptor 2 (HER2) gene (also referred to as ERBB2), 1, 2 which is amplified and/or overexpressed in approximately 15% to 20% of primary breast cancers. Since then, minor clarifications and updates to the ASCO/CAP HER2 testing guideline have been issued. [3] [4] [5] A detailed rationale for this full 2013 update, as well as additional background information, is available in Data Supplement 1.
In 2012, ASCO and CAP convened an Update Committee to conduct a formal and comprehensive review of the peer-reviewed literature published since 2006 and to revise the guideline recommendations as appropriate. Since publication of the 2007 guideline, new diagnostic strategies, like measures of HER2 amplification by bright-field in situ hybridization, DNA expression by microarray, or mRNA expression reverse-transcriptase polymerase chain reaction, have been introduced into practice, and the Update Committee felt these required evidence-based review. The Update Committee wishes to re-emphasize that it is important that any new test methodology, for the same clinical use, be compared with a reference test that assays for the same analyte and for which there are high levels of evidence that use of the test leads to clinical benefit for the patient (ie, clinical utility). It is the opinion of the Update Committee that there is insufficient evidence to support use of mRNA or DNA microarray assays to determine HER2 status in unselected patients (Data Supplement 2A).
Further experience with established HER2 assays also led to the identification of unusual HER2 genotypic abnormalities, like aneusomy of chromosome 17 (polysomy and monosomy), colocalization of HER2 and CEP17 signals that affect HER2/CEP17 ratio in dualsignal in situ hybridization (ISH) assays, and genomic heterogeneity. Limited retrospective data on the clinical significance of these abnormalities in completed prospective trials also guided the discussions that were part of this guideline update. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Some these issues are discussed in Data Supplements 2B and 2C and in a separate review article by Hanna et al. 23 During the deliberations, the Update Committee was concerned about false-negative and false-positive HER2 assessments. For example, a false-negative test result could lead to denial of trastuzumab treatment for a patient who could benefit from it. False-positive results could lead to the administration of potentially toxic, costly, and ineffective adjuvant HER2-targeted therapy for 1 year. [24] [25] [26] [27] The Update Committee considered mandatory testing of all HER2-negative tests (Data Supplement 2D) and addressed also a narrower set of scenarios that may on occasion be observed with dual-signal ISH assays (Data Supplement 2E; Interpretation Criteria If Using a Dual-Signal HER2 Assay and Average HER2 Copy Number Ͻ Six Signals Per Cell).
Trastuzumab had previously been shown to improve progression-free survival and overall survival when combined with chemotherapy in the metastatic setting. 28 Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year of trastuzumab administered with or after adjuvant chemotherapy. [29] [30] [31] Prospective randomized trials, first reported in abstract form in late 2012, seem to suggest that 12 months is the optimal duration of adjuvant trastuzumab therapy.
THE BOTTOM LINE (CONTINUED)
• Must report HER2 test result as indeterminate if technical issues prevent one or both tests (IHC and ISH) performed in a tumor specimen from being reported as positive, negative, or equivocal. This may occur if specimen handling was inadequate, if artifacts (crush or edge artifacts) make interpretation difficult, or if the analytic testing failed. Another specimen should be requested for testing, if possible, and a comment should be included in the pathology report documenting intended action.
• Must ensure that interpretation and reporting guidelines for HER2 testing are followed (Table 1 ; Data Supplements 7, 8, 9 , and 10).
• Should interpret bright-field ISH on the basis of a comparison between patterns in normal breast and tumor cells, because artifactual patterns may be seen that are difficult to interpret. If tumor cell pattern is neither normal nor clearly amplified, test should be submitted for expert opinion.
• Should ensure that any specimen used for HER2 testing (cytologic specimens, needle biopsies, or resection specimens) begins the fixation process quickly (time to fixative within 1 hour) and is fixed in 10% neutral buffered formalin for 6 to72 hours and that routine processing, as well as staining or probing, is performed according to standardized analytically validated protocols.
• Should ensure that the laboratory conforms to standards set for CAP accreditation or an equivalent accreditation authority, including initial test validation, ongoing internal quality assurance, ongoing external proficiency testing, and routine periodic performance monitoring.
• If an apparent histopathologic discordance is observed in any HER2 testing situation (Table 2) , the pathologist should consider ordering additional HER2 testing and conferring with the oncologist, and should document the decision-making process and results in the pathology report. As part of the HER2 testing process, the pathologist may pursue additional HER2 testing without conferring with the oncologist.
• Although categories of HER2 status by IHC or ISH can be created that are not covered by these definitions, in practice they are uncommon and if encountered should be considered IHC equivocal or ISH equivocal.
Methods
• Systematic review and analysis of the medical literature were conducted by the 2013 Update Committee. ) have been approved for the treatment of HER2-positive metastatic breast cancer. At the same time, data show that lapatinib (when added to paclitaxel) 35 and pertuzumab (as a single agent) 36 offer no clinical benefit in patients with HER2-negative metastatic disease. These new HER2-targeted drugs are now being tested in the adjuvant setting, including in studies evaluating their adjuvant role alone or in dual-antibody regimens without concomitant or sequential chemotherapy. Compared with regimens already in use, the newer agents are as or more expensive, and they may be associated with other dose-limiting toxicities, such as skin and GI tract toxicities with lapatinib and liver toxicities with ado-trastuzumab emtansine. 37 Therefore, the need for an updated ASCO/CAP guideline on accurate HER2 testing to ensure that the right patient receives the right treatment is now more critical than ever. 22, [24] [25] [26] [27] 38 Since the publication of the 2007 HER2 testing guideline, CAP has observed a remarkable uptake of proficiency testing (Fig 4) , 5 with nearly 1,500 laboratories currently participating. CAP has also observed fewer laboratories experiencing deficiencies on laboratory inspection. Indirect evidence suggests that the performance of laboratories that conduct HER2 testing in the United States and elsewhere is improving.
Additional Information
39-42 Available evidence and experience since 2007 reinforce the importance of robust validation of new assays by laboratories before clinical implementation, as well as their ongoing monitoring, and the value of various external quality assurance schemes adopted in many countries.
METHODS
The HER2 testing Update Committee (Appendix Table A1 , online only) met three times via Webinars coordinated by its Steering Committee to review the data published from January 2006 to January 2013 and to revise the recommendations. Additional data were gathered from in-press publications and personal correspondence with researchers to address the issue of mandatory testing if a test result is 0 or 1ϩ. Draft manuscripts were circulated by e-mail, and the Update Committee approved the final manuscript. This guideline was reviewed by external reviewers and approved by the ASCO Clinical Practice Guideline Committee and relevant CAP entities.
Literature Search Strategy
The MEDLINE and the Cochrane Collaboration Library electronic databases were searched with the date parameters of January 2006 through January 2013 for articles in English. The MEDLINE search terms are included in Data Supplement 3, and a summary of the literature search results is provided in Data Supplement 4.
Inclusion and Exclusion Criteria
Articles were selected for inclusion in the systematic review of the evidence if they met the following criteria : (1) the study compared, prospectively or retrospectively, fluorescent ISH (FISH) and immunohistochemistry (IHC) results or other tests; described technical comparisons across various assay platforms; examined potential testing algorithms for HER2 testing; or examined the correlation of HER2 status in primary versus metastatic tumors from the same patients; (2) the study population consisted of patients with a diagnosis of invasive breast cancer; or (3) the primary outcomes included the negative predictive value (NPV) or positive predictive value (PPV) of ISH and IHC assays used to determine HER2 status, alone and in combination; negative and positive concordance across platforms; and accuracy in determining HER2 status and benefit from anti-HER2 therapy and in determining sensitivity and specificity of individual tests. Consideration was given to studies that directly compared results across assay platforms.
Studies were not limited to randomized controlled trials but also included other study types, including cohort designs, case series, evaluation studies, and comparative studies. The Update Committee also reviewed other testing guidelines and proficiency strategies of various US and international organizations, including unpublished data. Letters, commentaries, and editorials were reviewed for any new information. Case reports were excluded. The clinical questions addressed in the update are available in Data Supplement 5. This information was used to help the Update Committee develop new algorithms (for pathologists and oncologists) for testing, specify testing requirements and exclusions, and facilitate the necessary quality assurance monitoring that will make HER2 testing less variable and ensure more analytic consistency between laboratories. The term ratio, as used in the guideline recommendations and algorithms, always applies to the HER2/CEP17 ratio, which means the ratio of HER2 signals per cell (numerator) over CEP17 signals per cell (denominator).
ASCO Guideline Disclaimer
The clinical practice guideline and other guidance published herein are provided by ASCO to assist practitioners in clinical decision making. The information herein should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified herein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating physician, because the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of terms like must, must not, should, and should not indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating physician in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an as-is basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.
CAP Guideline Disclaimer
Clinical practice guidelines reflect the best available evidence and expert consensus supported in practice. They are intended to assist physicians and patients in clinical decision making and to identify questions and settings for further research. With the rapid flow of scientific information, new evidence may emerge between the time a practice guideline or consensus statement is developed and when it is published or read. Guidelines and statements are not continually updated and may not reflect the most recent evidence. Guidelines and statements address only the topics specifically identified therein and are not applicable to other interventions, diseases, or stages of diseases. Furthermore, guidelines and statements cannot account for individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It is the responsibility of the treating physician, relying on independent experience and knowledge, to determine the best course of treatment for the patient. Accordingly, adherence to any practice guideline or consensus statement is voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circumstances and preferences. CAP makes no warranty, express or implied, regarding guidelines and statements and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. CAP assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this statement or for any errors or omissions.
Guideline and Conflicts of Interest
The Update Committee was assembled in accordance with CAP and ASCO Conflicts of Interest Management Procedures for Clinical Practice Guidelines (ASCO procedures are summarized at http://www.asco.org/ guidelinescoi). Members of the Update Committee completed the ASCO disclosure form, which requires disclosure of financial and other interests that are relevant to the subject matter of the guideline, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as the result of promulgation of the guideline. Categories for disclosure include employment relationships, consulting arrangements, stock ownership, honoraria, research funding, and expert testimony. In accordance with the procedures, the majority of the members of the Update Committee did not disclose any such relationships.
RECOMMENDATIONS

CLINICAL QUESTION 1
What is the optimal testing algorithm for the assessment of HER2 status?
Literature Update and Discussion
The Update Committee found more than 70 new publications that informed a revision of the testing algorithms contained in the original 2007 guideline. At the time of the original guideline, significant concern existed about false-positive HER2 test results. Guideline recommendations emphasized those changes that would mitigate false positives, particularly relating to issues of specimen fixation and pathologist interpretation.
39,43-47 Preliminary data from an ongoing prospective study seem to suggest that the frequency of false-positive test results may have diminished, in that the concordance between local testing in laboratories throughout the United States and confirmatory central HER2 testing at the Mayo Clinic (Rochester, MN) for the ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization HER2 Adjuvant Trial) trial showed that less than 6% of patients initially considered eligible were not subsequently centrally confirmed as being HER2 positive.
48
On the other end of the spectrum, clinical experience and recent literature have indicated that false-negative HER2 test results must also be considered. The Update Committee was sensitive to the concerns that surfaced after the publication of the 2007 guideline about the very small number of patients potentially affected by the recommendation to consider as HER2 positive only those tumors with more than 30% of cells (or Ͼ 10% to Յ 30% if HER2 amplified by FISH) with diffuse and intense circumferential staining.
49 Therefore, the Update Committee decided to revert to the previously used IHC criterion of more than 10% cells staining for HER2, which had been used as an entry criterion for eligibility for the first generation of prospective randomized trials of adjuvant trastuzumab. 18, 22, [49] [50] [51] [52] [53] The rationale for this recommendation by the Update Committee is detailed in Data Supplement 1. Aside from the very small number of patients affected (as few as 0.15% of all newly diagnosed patients, as previously discussed), 5 the Update Committee was also of the opinion that improvements in analytic performance of HER2 testing in clinical practice since 2007 have further reduced the already small number of patients potentially at risk of receiving a false-negative test result.
Testing is now recommended for primary, recurrent, and metastatic tumors. 19, 35, 45, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] 64 Tissue from the primary tumor can be obtained through a core needle biopsy, as well as from an incisional and excisional surgical procedure. 65 Metastases can be biopsied from chest wall, regional lymph nodes, or distant organs. [66] [67] [68] [69] [70] [71] [72] [73] [74] It is essential to ensure that time to fixation (cold ischemic time) and time in fixative (which has increased from 6 to 48 hours to 6 to 72 hours in this Update on the basis of available data and to conform with the ASCO/CAP estrogen receptor [ER]/progesterone receptor [PgR] testing guideline 75, 76 ) are recorded and considered in defining the test result. More detail about preanalytic issues is available in Data Supplement 6.
In summary, if available, perform the first test in the core biopsy specimen in a patient with newly diagnosed breast cancer. If the test result is clearly positive or clearly negative as defined in Table 1 , no retesting is needed. If the test is negative and there is apparent histopathologic discordance (Table 2) , or if specimen handling has not been in accordance with guideline recommendations, a section of the tumor from the excisional specimen should be tested. If this result is positive, no further testing is needed. However, if the test is negative and there remains significant clinical concern about the result after consultation between the pathologist and the medical oncologist, it may be appropriate to repeat the test in a different block from the patient's tumor. If all three tests are negative, no additional testing is recommended.
Data Supplement 7 is a table of IHC Interpretation Criteria, and Data Supplement 8 provides ISH Interpretation Criteria. Both of these Data Supplements expand on details provided in Table 1 .
The Update Committee clarified several issues in the Update on the basis of recently published literature. The recommendations in Table 1 
HER2 Assay Exclusions
Each assay type has diagnostic pitfalls to be avoided. The Update Committee agreed that there were situations in which one assay type was preferred because of assay or sample considerations. Exclusion criteria to perform or interpret an IHC or any ISH assay for HER2 are unchanged but can be viewed in the original guideline.
1,2 The pathologist who reviews the histologic findings should determine the optimal assay (IHC or ISH) for determination of HER2 status.
Algorithms for HER2 Testing by IHC and ISH
Algorithms for evaluation of HER2 protein expression by IHC and HER2 amplification by single-probe or dual-probe ISH are presented in Figures 1, 2 , and 3.
CLINICAL QUESTION 2
What strategies can help ensure optimal performance, interpretation, and reporting of established assays?
Literature Update and Discussion
Testing analytic validation requirements. The Update Committee reviewed new papers and reports on strategies to ensure optimal performance, interpretation, and reporting of assays. 16, 22, 100, 136, 137 Most new HER2 assays have been submitted to the FDA for premarket approval review as class III devices in view of their use for therapy selection. Although a new HER2 assay ideally should have its clinical utility validated using specimens from prospective therapeutic trials that tested the effects of anti-HER2 therapy, the Update Committee recognizes that the rarity of these valuable specimens requires that new HER2 assays be approved on the basis of concordance studies comparing them with other established HER2 tests. Consequently, it is important that tissues selected for such concordance studies come from datasets that include a broad representation of patients with breast cancer in whom HER2-positive status will be observed in approximately 15% to 20%.
Ongoing competency assessment. The Update Committee urges ongoing competency assessment as a part of every laboratory's internal quality assessment program. The competency of the laboratory professionals and pathologists interpreting assays must be continuously addressed as required under the Clinical Laboratory Improvements Amendments (CLIA 88). The acceptable performance standard for such competency tests remains the same as in the original guideline.
Reporting requirements. Data Supplements 9 and 10 are tables of reporting elements for IHC and reporting elements for ISH, respectively. Some changes have been made to the reporting elements for IHC and ISH to ensure that they are in accordance with the revised recommendations. In addition, a disclaimer statement is required if the specimen handling requirements are not met.
New interpretation requirements relate to the definition of tumor samples with genomic heterogeneity as well as the examination of specimens and interpretation of results in these samples. No specific requirements were added for designation of polysomy by ISH. Laboratories should maintain documentation of their quality assurance practices and ensure that such documentation is available for inspection.
Regulatory framework. The regulatory framework remains the same as discussed in the original guideline. At the current time, the FDA exercises enforcement discretion over laboratory-developed tests (LDTs) that are generated and performed within an individual laboratory under CLIA 88. CLIA 88 provides stringent quality standards for highly complex tests, which include all predictive cancer factor assays. This legislation also requires biannual surveys of laboratories that perform highly complex tests, with defined criteria and actions required when performance is deficient. However, CLIA certification does not require that the tests performed have been shown with a high level of evidence to have clinical utility. 138, 139 Moreover, FDA approval of devices, which includes in vitro diagnostic tests such as those discussed in this guideline, does not necessarily require demonstration that use of the assay results in improved clinical outcomes compared with not using the assay. The Update Committee expresses concern about the need for greater clarity in the regulatory environment with regard to companion diagnostic tests and LDTs for higher-risk tumor biomarker tests, such as HER2. Some of this has been discussed by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative and endorsed by the Institute of Medicine Committee in regard to omics-based tests, as well as others, 139 and the Update Committee understands the FDA is developing a risk-based framework to address concerns about test accuracy and clinical utility. Reporting requirements for all assay types Report must include guideline-detailed elements Same except for changes to reporting requirement and algorithms defined in this table (Data Supplements 9 and 10).
Optimal tissue handling requirements Time from tissue acquisition to fixation should be as short as possible; samples for HER2 testing are fixed in 10% neutral buffered formalin for 6-48 hours; cytology specimens must be fixed in formalin.
Duration of fixation has been changed from 6-48 hours to 6-72 hours. Any exceptions to this process must be included in report.
Samples should be sliced at 5-to 10-mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of neutral buffered formalin (continued on following page) If a reflex test (same specimen/same tissue) ordered after an initial equivocal HER2 test result does not render a positive or negative HER2 test result, the pathologist should review histopathologic features, confer if possible with the oncologist regarding additional HER2 testing, and document it in the pathology report. The pathologist may pursue additional HER2 testing without conferring with the oncologist. This should be accomplished using: (1) the alternative test (IHC or ISH) on the same specimen, (2) either test on another block (same specimen), or (3) either test on another specimen (eg, core biopsy, surgical resection, lymph node, and/or metastatic site). Because the decision to recommend HER2-targeted therapy requires a HER2-positive test result, additional HER2 testing should be attempted in equivocal specimens to attempt to obtain a positive or negative HER2 test result and most accurately determine the HER2 status of the tumor specimen. Alternatively, a laboratory accredited by CAP or another accrediting entity may choose to use an LDT, in which case its analytical performance must be documented in the same clinical laboratory that will use the assay, and documentation of analytical validity of the assay must be available.
h A list of HER2 assays approved by the FDA as in vitro companion diagnostic devices to aid in the assessment of patients for whom trastuzumab treatment is being considered can be found in the Medical Devices section of the US FDA Web site (http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?start_searchϭ1&search_termϭHER2&approval_date_fromϭ&approval_date_toϭ07/14/2013&sortϭ approvaldatedesc&pagenumϭ10; last checked July 14, 2013). The product package insert for trastuzumab and pertuzumab prepared by the FDA indicates that "HER2 testing should be performed using
Optimal external quality assurance methods to ensure accuracy in HER2 testing and laboratory accreditation. External proficiency testing is a mandatory requirement for CAP-accredited laboratories, beginning with the 2007 guideline. External proficiency testing challenges failure requires investigation and corrective action before the laboratory can continue to offer HER2 testing.
CAP modified its laboratory accreditation program to include more careful scrutiny of HER2 testing, thus creating a mandatory and expanded proficiency testing program to evaluate laboratory performance. The systematic review revealed many new papers on quality assurance, quality improvement, proficiency testing, and establishment of concordance between local and central laboratories, both in Histologic grade 1 carcinoma of the following types: Infiltrating ductal or lobular carcinoma, ER and PgR positive Tubular (at least 90% pure) Mucinous (at least 90% pure) Cribriform (at least 90% pure) Adenoid cystic carcinoma (90% pure) and often triple negative If the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test must be ordered on the excision specimen if one of the following is observed: Tumor is grade 3 Amount of invasive tumor in the core biopsy is small Resection specimen contains high-grade carcinoma that is morphologically distinct from that in the core Core biopsy result is equivocal for HER2 after testing by both ISH and IHC There is doubt about the specimen handling of the core biopsy (long ischemic time, short time in fixative, different fixative) or the test is suspected by the pathologist to be negative on the basis of testing error
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; PgR, progesterone receptor. The number of laboratories participating in predictive marker proficiency testing for HER2 and ER as part of the CAP laboratory improvement program since 2004isshowninFigure4,andtheprogram is described at http://www.cap.org/apps/cap.portal?_nfpbϭtrue&_ pageLabelϭaccreditation (last checked July 14, 2013).
Ongoing Communication, Education, and Evaluation Efforts by CAP
CAP has undertaken comprehensive efforts to educate pathologists about ways to improve laboratory performance of HER2, ER, and PgR assays. Numerous live and online educational offerings are available from CAP and other organizations. Examples in North America include the American Society of Clinical Pathology (ASCP) and United States and Canadian Academy of Pathology (USCAP). CAP provides varied live and online education focused on HER2 and ER/ PgR testing elements of relevance to pathologists in meeting the original ASCO/CAP HER2 and ER/PgR guidelines and updates. In follow-up surveys, participants routinely report they made changes to their practice as a result of the educational experience. Many of these learning opportunities have a scored assessment component, allowing participants to test their knowledge as part of completing the courses, and can be used to meet the American Board of Pathology (ABP), the US pathologist certifying organization, Maintenance of Certification requirements. More information can be found at the CAP learning portal (http://www.cap.org) and in the original guideline. CAP has also created a listing of competencies in breast pathology, compiled by experts and available for pathologist self-assessment. After taking this self-assessment, pathologists are prompted to learning offerings that target those areas of self-reported educational deficiency. A listing of the courses is available online at http://www.cap.org via the learning portal.
STUDY QUALITY, LIMITATIONS OF THE LITERATURE, AND FUTURE RESEARCH
Whether in the context of trastuzumab clinical trials or of studies comparing HER2 testing platforms, interpretation of the literature in the field of HER2 testing is still complicated by a lack of standardization across trials in assay utilization and interpretation, presence or absence of confirmatory testing, and local versus central laboratory testing, among other considerations. Although FDA-approved assays have been carefully validated, not all LDTs may have, which complicates direct comparisons across trials and platforms, and we maintain that this situation leaves open the possibility that a substantial percentage of some patients with breast cancer could be either over-or undertreated with HER2-targeted therapies. An important gap in the literature identified by the Update Committee concerns those patients with test results reported as equivocal. The decision to treat with specific therapies like trastuzumab is by necessity dichotomous (yes or no) and will not be informed by an Algorithm for evaluation of human epidermal growth factor receptor 2 (HER2) gene amplification by in situ hybridization (ISH) assay of the invasive component of a breast cancer specimen using a dual-signal (HER2 gene) assay (dual-probe ISH). Amplification in a dual-probe ISH assay is defined by examining first the HER2/CEP17 ratio followed by the average HER2 copy number (see Data Supplement 2E for more details). If there is a second contiguous population of cells with increased HER2 signals per cell, and this cell population consists of more than 10% of tumor cells on the slide (defined by image analysis or visual estimation of the ISH or immunohistochemistry [IHC] slide), a separate counting of at least 20 nonoverlapping cells must also be performed within this cell population and also reported. Although categories of HER2 status by ISH can be created that are not covered by these definitions, in practice they are rare and if encountered should be consideredequivocal diagnosis with respect to HER2 status without repeat testing, if possible. However, HER2 test results are derived from a continuous variable, which can be expected to lead to some results falling into a gray area. Adding to this confusion is the fact that there is variability in the reporting definitions of the equivocal ranges for both bright-field ISH and FISH assays.
The literature is lacking evidence on response to HER2-targeted therapy in the subgroup of patients with equivocal results, and there are limited efficacy data in the subgroup tested with both high quality IHC and FISH and found to have a discordant result between these two tests. Patients with such results constitute poorly studied subsets for which there is less confidence in the scores and actual benefit from trastuzumab therapy. Because the retrospective evaluation of the benefit from trastuzumab in patients with apparent discordance between IHC and FISH who were enrolled onto the first generation of trastuzumab trials included only a small number of patients in each of the discordant subsets, patients who would have qualified for enrollment in those trials should be considered for HER2-targeted therapy.
The Update Committee's goal was to address the most common clinical situations encountered by pathologists and oncologists in routine clinical practice. Specifically in regard to ISH assays, it expected that additional but rare categories of HER2 status by ISH could be created that are not covered by the definitions illustrated in Figures 2  and 3 . Data Supplement 2E addresses a narrower set of scenarios that may on occasion be observed with dual-signal ISH assays.
For patients with low levels of HER2 expression that do not reach the threshold for HER2-positive disease, the Update Committee encourages enrollment of such patients, if eligible, onto prospective clinical trials that aim to address the value of adjuvant HER2-targeted therapies in patients whose breast cancers show low levels of HER2 expression, like the NSABP B-47 (National Surgical Adjuvant Breast and Bowel Project B-47) trial (NCT01275677). The Update Committee also supports participation in studies evaluating other cutoffs and other technologies to optimize eligibility for HER2-targeted therapies.
PATIENT AND CLINICIAN COMMUNICATION
Patients (and family members or caregivers) should be educated about the results of pathology tests and how they are used to develop a treatment plan tailored to the biology of their cancers. Because many newly diagnosed patients are under emotional stress and/or may be unaccustomed to complex medical terminology, the use of easily understood language (at an educational level that the patient can understand) is key to clear communication. Asking patients to repeat back key pieces of information, providing written or recorded notes, and using visual aids can help ensure information is effectively communicated.
Patients should be given a copy of their pathology report and HER2 test results. The clinician should review the results with the patient, discuss any issues with the test interpretation or performance, and ask if he or she has any additional questions about the results.
Key Points for Clinicians to Discuss With Patients Regarding HER2 Status
Explain the importance of determining the biologic characteristics of breast cancer. Patients should understand that the most common biologic tests are those for ER, PgR, and HER2 and that testing for these markers is important to select an appropriate treatment. The overall percentage of patients with HER2-positive breast cancer is between 15% and 20%. Observed numbers may vary depending on the population being tested by individual laboratories.
Explain the importance of HER2 testing. Patient should understand that HER2 status determines whether certain drugs (eg, trastuzumab, lapatinib, pertuzumab, T-DM1) are recommended. They should also understand that the HER2 gene is important in tumor cell growth and that tumors that have increased levels of HER2 (as measured by HER2 gene amplification or HER2 protein overexpression) usually have a higher growth rate and a more aggressive clinical behavior.
Explain the type of tissue used for HER2 testing. Patients should understand the type of tissue used for HER2 testing (eg, core biopsy, excisional biopsy).
Explain additional testing using an alternative test or using the same or alternative test on a different portion of the same specimen (different block). Sometimes, the oncologist or pathologist may recommend additional testing using a different type of tumor specimen (eg, surgical excision v core biopsy), if available. Patients should be informed about which test or tests were performed and the expected turnaround time for these tests. Unfortunately, some results remain indeterminate or inconsistent with other histopathologic findings. In such cases, a final treatment decision to consider treatment with HER2-targeted therapy should be made after consultation between the pathologist and oncologist and a discussion with the patient.
Explain the importance of retesting HER2 status in new, metastatic tumors. Patients should understand that HER2 status may occasionally be different (discordant) when comparing a previous primary tumor and a site of recurrence or in the setting of multiple simultaneous metastatic sites. In some cases, it is not possible to fully differentiate between a true biologic change, tumor heterogeneity, or variability in the performance of the assay.
Explain that HER2 testing guidelines exist. Patients should be assured that HER2 testing guidelines were followed. Refer patients to the ASCO/CAP guideline update at www.asco.org/guideline/her2 and/or http://www.cap.org and to www.cancer.net for additional patient-focused information.
HEALTH DISPARITIES
Although ASCO clinical practice guidelines present recommendations on the best practices in diagnosis and disease management to provide the highest level of cancer diagnosis and care, it is important to note that some racial/ethnic minority patients have limited access to optimal medical care and/or accredited pathology laboratories. At the same time, some Medicaid or uninsured patients may have access to accredited pathology laboratories by virtue of receiving some or all of their care in an academic medical center. [147] [148] [149] [150] Disparities clearly exist in the likelihood of receiving HER2 testing. 155 also reported that women with capitated insurance (v fee-for-service insurance) were significantly more likely to be tested for HER2 status. Awareness of possible disparities in access to care should be considered in the context of this clinical practice guideline, and health care providers should strive to deliver the highest level of cancer care to these vulnerable populations.
ADDITIONAL RESOURCES
Data Supplements, including evidence tables, and clinical tools and resources can be found at www.asco.org/guidelines/her2. Information for patients is available at http://www.cancer.net. 81. Tse CH, Hwang HC, Goldstein LC, et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-
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